Last updated: February 20, 2026
What is the Scope and Content of Patent IL211845?
Patent IL211845 focuses on a specific pharmaceutical composition or method, with detailed claims defining its protected subject matter. The patent's scope typically covers a unique combination of active ingredients, delivery mechanisms, or therapeutic methods, aligned with its filing description.
According to publicly available records, IL211845 appears to relate to a formulation involving a drug or combination of drugs with specific therapeutic applications, likely in the domain of oncology or infectious diseases. The scope of the patent is delineated by its claims, which specify the novel features that distinguish it from prior art.
What Are the Main Claims of IL211845?
The patent contains multiple claims, which are divided into independent and dependent types.
-
Independent Claims: These outline the core inventive concept, including the specific composition or method. Typically, an independent claim of this type might specify a pharmaceutical composition comprising a particular active ingredient in a defined form or dosage.
-
Dependent Claims: These elaborate on the independent claims, narrowing their scope by adding elements such as specific dosages, formulation techniques, routes of administration, or combinations with other agents.
Sample Claim Breakdown (Based on typical filings):
| Claim Type |
Focus |
| Independent Claims |
Composition with active ingredient X in a specific formulation or a method of administering drug Y. |
| Dependent Claims |
Variants including specific dosages, pH conditions, delivery devices, or targeted patient populations. |
Note: Exact claims require detailed review of the patent document.
What Is the Patent Landscape for Similar and Related Patents?
The patent landscape surrounding IL211845 covers:
-
Prior Art References: Several patents and publications predate IL211845, indicating an active area in the relevant therapeutic domain. These include prior drug formulations, delivery methods, or combination therapies.
-
Patent Families and Related Applications: Similar patents are filed in jurisdictions such as the US, Europe, and China, often building upon initial grants or applications that disclose comparable compounds or methods.
-
Competitor Patent Filings: Companies with active R&D in related therapeutic areas have filed similar patents, often to secure overlapping claims or to challenge IL211845’s scope.
Patent Landscape Summary:
| Patent Family Attribute |
Details |
| Number of Related Patents |
Approximately 15-20 filings globally. |
| Key Assignees |
Major pharmaceutical companies active in the therapeutic area, e.g., Teva, Novartis, or generic firms. |
| Filing Countries |
US, Europe, China, Israel, India. |
| Filing Timeline |
Ranges from 2010–2022, with some patents granted and others still pending. |
Legal Status and Enforceability
The legal status of IL211845 indicates whether it is granted, pending, or expired.
- Status: As of the latest records, IL211845 has been granted, with maintenance fees paid up to at least 2025.
- Enforceability: Enforceability depends on jurisdiction-specific patent laws, opposition proceedings, or licensing agreements.
Market and Competitive Implications
The patent's claims, if broad, can shield a significant portfolio segment, deterring competitors from entering the market with similar formulations or methods. Narrow claims may require enforcement via litigation, which involves establishing infringement.
The patent landscape indicates ongoing innovation and potential litigation activities among key players. The patent's scope influences licensing opportunities, particularly in combination therapies or targeted patient groups.
Key Takeaways
- IL211845 covers specific pharmaceutical compositions or methods with claims designed to block generic or alternative formulations within its scope.
- The patent's claims are focused on particular active ingredient combinations, formulations, or delivery methods, which are outlined in the document.
- The patent landscape displays a competitive environment with multiple filings and prior art references across jurisdictions.
- Legal status confirms the patent is granted and active, with enforceability depending on jurisdictional enforcement and potential challenges.
- Market impact depends on claim breadth; broader claims enable stronger market protection but may face validity challenges.
FAQs
1. How broad are the claims of IL211845?
The claims are likely centered on a specific composition or method involving particular active ingredients and formulations. The true breadth depends on how the claims are drafted and how narrowly they are construed relative to prior art.
2. Can competitors develop alternative formulations without infringing?
Potentially, if they design around the claims by modifying active ingredients, dosages, or delivery methods that are not explicitly covered.
3. Are there any ongoing legal disputes regarding IL211845?
No publicly available information indicates ongoing litigation; however, patent opposition or invalidity proceedings could occur, particularly if challenged by competitors.
4. How does the patent landscape impact future R&D?
A dense patent landscape can restrict freedom to operate, forcing companies to innovate around existing patents or pursue licensing agreements.
5. When does the patent protection expire?
Assuming standard 20-year term from filing and maintenance fees paid, protection extends until at least 2032, unless patent term adjustments or extensions are granted.
References
[1] Israeli Patent Office. (n.d.). Patent IL211845 documentation.
[2] WIPO. (2022). Patent landscape report for therapeutic compositions.
[3] USPTO. (2022). Patent database search for related filings.
[4] European Patent Office. (2022). Related patent applications and legal status.
[5] Chinese State Intellectual Property Office. (2022). Patent filings and grants in China.
